Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Karolinska University Hospital | OTHER |
| Sahlgrenska University Hospital | OTHER |
| Helse Fonna | OTHER |
| University Hospital of North Norway |
Not provided
Not provided
Not provided
Not provided
The main objective of this study is establish the performance of miR371 in management of testicular cancer
The main objective of the study is to asses the sensitivity and specificity of microRNA-371a-5p (miR371) in detection of viable testicular germ tumour cells. To assess the utility of miR371 at orchiectomy, during treatment and surveillance and in early detection of recurrence.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biomarker analysis | Other | Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months |
| Measure | Description | Time Frame |
|---|---|---|
| miR371 as a biomarker in testicular germ cell cancer at orchiectomy | To estimate the sensitivity and specificity of miR371 in identifying viable tumour cells at diagnosis | 5 years |
| miR371 as a biomarker in testicular germ cell cancer at RPLND | To estimate the sensitivity and specificity of miR371 in identifying viable tumour cells at RPLND | 5 years |
| miR371 as a biomarker in testicular germ cell cancer during chemotherapy treatment | To estimate the performance of miR371 in monitoring of treatment efficiency (chemotherapy) | 5 years |
| miR371 as a biomarker in testicular germ cell cancer and detection of recurrence | To estimate the performance of miR371 in (early) detection of recurrence | 5 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Testicular Germ Cell Cancer
Men with suspected and confirmed testicular germ cell cancer, aged 18-70 years. Seminomas and non-seminomas, stage I-IV.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mette Pernille Myklebust, PhD | Contact | +47 41684492 | mette.pernille.myklebust@helse-bergen.no | |
| Olav Dahl, PhD | Contact | +47 55972081 | olav.dahl@helse-bergen.no |
| Name | Affiliation | Role |
|---|---|---|
| Mette Pernille Myklebust, PhD | Haukeland University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Haukeland University Hospital | Recruiting | Bergen | 5021 | Norway |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| OTHER |
| Oslo University Hospital | OTHER |
Not provided
Not provided
Not provided
Blood is collected in order to extract RNA.
| Haugesund Hospital | Recruiting | Haugesund | 5528 | Norway |
|
| Oslo University Hospital | Not yet recruiting | Oslo | 0379 | Norway |
|
| University Hospital of North Norway | Recruiting | Tromsø | 9038 | Norway |
|
| Sahlgrenska University Hospital | Not yet recruiting | Gothenburg | 41345 | Sweden |
|
| Karolinska University Hospital | Recruiting | Stockholm | Sweden |
|
| ID | Term |
|---|---|
| D013736 | Testicular Neoplasms |
| D018239 | Seminoma |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D004700 | Endocrine System Diseases |
| D013733 | Testicular Diseases |
| D006058 | Gonadal Disorders |
| D018237 | Germinoma |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided